Tag: Committee for Medicinal Products for Human Use
-
Syfovre Safety-Benefit Assessment by Europe’s Drug Regulator Differs From FDA
EMA’s CHMP Does Not Approve Syfovre for a Second Time, Citing "significant risk of adverse events" (Posted by Tom Lamb at Drug Injury Watch) There seems to be some disagreement about the Syfovre safety-benefit assessment…
-
Fall 2012: Two Recent Medical Reports Regarding Safety Of Pradaxa, Boehringer Ingelheim’s Anticoagulation Drug
Use Of Pradaxa After ACS Is Associated With Increased Rate Of Major Bleeding, And Concomitant Use Of Pradaxa With Multaq Is Contraindicated (Posted by Tom Lamb at DrugInjuryWatch.com) When Pradaxa (dabigatran) is used to prevent…